Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASE1 | P07998 | 1/20 | 0.61 |
| ▸ | TK1 | P04183 | 6/20 | 0.54 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.54 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11986879 | 1.00 | RNASE1 (0.61) | RNASE1TK1ABCG2ABCB1 | |
| SCHEMBL2327879 | 1.00 | RNASE1 (0.61) | RNASE1TK1ABCG2ABCB1 | |
| SCHEMBL4278972 | 1.00 | RNASE1 (0.61) | RNASE1TK1ABCG2ABCB1 | |
| SCHEMBL31227958 | 1.00 | RNASE1 (0.61) | RNASE1TK1ABCG2ABCB1 | |
| SCHEMBL32668971 | 1.00 | RNASE1 (0.61) | RNASE1TK1ABCG2ABCB1 | |
| SCHEMBL13948025 | 1.00 | RNASE1 (0.61) | RNASE1TK1ABCG2ABCB1 | |
| SCHEMBL4278968 | 1.00 | RNASE1 (0.61) | RNASE1TK1ABCG2ABCB1 | |
| SCHEMBL12969271 | 1.00 | RNASE1 (0.61) | RNASE1TK1ABCG2ABCB1 | |
| SCHEMBL22143532 | 1.00 | RNASE1 (0.61) | RNASE1TK1ABCG2ABCB1 | |
| SCHEMBL4495987 | 0.94 | RNASE1 (0.64) | RNASE1TK1ABCG2ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1348712-B1 | Processes and intermediates in the synthesis of L-thymidine | MITSUI CHEMICALS INC (JP) | 2011-05-04 | — | — | EP | disclosed |
| US-7125983-B2 | L-nucleic acid derivatives and process for the synthesis thereof | MITSUI CHEMICALS, INC. (JP) | 2006-10-24 | — | — | US | disclosed |
| US-20040063926-A1 | L-nucleic acid derivative and processes for the synthesis thereof | MITSUI CHEMICALS, INC. (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-1348712-A1 | L-NUCLEIC ACID DERIVATIVES AND PROCESSES FOR THE SYNTHESIS THEREOF | Mitsui Chemicals, Inc. (JP) | 2003-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063926-A1 | L-nucleic acid derivative and processes for the synthesis thereof | TYMS, RNGTT, DTYMK | RNASE1 366/4885TK1 23/4885ABCG2 2322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.